Balyasny Asset Management
HZNP

Balyasny Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Balyasny Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-726,000
Closed -$84M – 3045
2023
Q3 		$84M Sell
726,000
-78,700
-10% -$8.46M 0.17% 133
2023
Q2 		$82.8M Buy
+804,700
New +$84.9M 0.18% 131
2023
Q1 		– Sell
-1,852,000
Closed -$211M – 3444
2022
Q4 		$211M Buy
1,852,000
+1,838,000
+13,129% +$153M 0.58% 9
2022
Q3 		$866K Buy
+14,000
New +$978K ﹤0.01% 1861

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's HZNP Position: Q4 2023 in Review

Balyasny Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,212,745 shares — an estimated $256M sold.

Balyasny Asset Management first reported a position in HZNP in Q1 2016 and held it in 24 quarters. The position peaked at $256M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Balyasny Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 2,212,745 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $256M.
  • Balyasny Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 24 quarters.
  • Balyasny Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $256M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.